Skip to content
← Full study record

NCT00719901 · MORE INFO

Limitations, agreements, and source contact

Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma · Source last updated 2015-01-12

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
pi Sponsor Employee
false
restriction Type
LTE60
restrictive Agreement
true
limitations And Caveats
description
This trial was terminated due to slow accrual and the drug supply of Obatoclax during the phase I; therefore, the phase II portion will never open. No results from the phase II portion are available.
point Of Contact
email
stewart.keith@mayo.edu
organization
Mayo Clinic
phone
480-301-4411
title
A. Keith Stewart
Complete source fields
certain Agreement
pi Sponsor Employee
false
restriction Type
LTE60
restrictive Agreement
true
limitations And Caveats
description
This trial was terminated due to slow accrual and the drug supply of Obatoclax during the phase I; therefore, the phase II portion will never open. No results from the phase II portion are available.
point Of Contact
email
stewart.keith@mayo.edu
organization
Mayo Clinic
phone
480-301-4411
title
A. Keith Stewart

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice